Dupilumab Improves Sleep Quality among Chronic Rhinosinusitis patients with nasal polyps
Chronic rhinosinusitis with nasal polyps (CRSwNP) has long been a source of discomfort for many, impacting patients' quality of life and sleep. Now, a promising development offers new hope. A recent study published in the Annals of Allergy, Asthma & Immunology Journal found that Dupilumab, a monoclonal antibody, can significantly improve the sleep quality of CRSwNP patients in real-life settings.
The most common form of CRSwNP is characterized by type 2 inflammation, marked by increased levels of interleukin (IL)-4, IL-5, and IL-13. Dupilumab works by targeting the IL-4 receptor-α, inhibiting signals from both IL-4 and IL-13, and has recently received approval for CRSwNP treatment.
In a study involving 29 consecutive patients, the impact of Dupilumab on sleep quality was examined over a three-month period. Before treatment, these patients reported sleep quality issues, with excessive daytime sleepiness affecting 24.1%, 79.3% reporting insomnia, and a staggering 93.1% experiencing globally impaired sleep quality.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.